What it takes to leverage AI in pharma and biotech R&D

In March 2024 John Rountree, Managing Director of Novasecta, facilitated Chatham-House-Rules discussion for senior executives in the biotech and pharmaceutical sectors, focusing on how firms can make the most of (Artificial Intelligence) AI for their Research and Development (R&D) efforts. This report summarises insights from the workshop. With transparency, realism, and a truly multi-disciplinary and […]

Data deals for an AI biotech

Challenge An AI drug discovery biotech sought drug discovery data from both failed and successful assets to train its algorithms. Management wanted to understand MidPharma appetite for and concerns over providing their drug discovery data in creative deal structures, so that it could consider how to further evolve its data strategy. Solution Engaged with the […]